---
title: "\"Performance\" QYUNS's annual net profit is 314 million RMB, turning losses into profits"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280908837.md"
description: "QYUNS-B announced its 2025 annual performance, with revenue of 807 million RMB (same below), an increase of 408.2% year-on-year. It recorded a net profit of 314 million RMB, compared to a loss of 336 million RMB in the previous year, turning from loss to profit; earnings per share were 1.41 RMB. No final dividend will be distributed"
datetime: "2026-03-29T11:49:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280908837.md)
  - [en](https://longbridge.com/en/news/280908837.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280908837.md)
---

# "Performance" QYUNS's annual net profit is 314 million RMB, turning losses into profits

QYUNS-B (02509.HK) announced its 2025 annual results, with revenue of 807 million RMB, an increase of 408.2% year-on-year. It recorded a net profit of 314 million RMB, turning from a loss of 336 million RMB in the previous year; earnings per share were 1.41 RMB. No final dividend was declared

### Related Stocks

- [159102.CN](https://longbridge.com/en/quote/159102.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [560600.CN](https://longbridge.com/en/quote/560600.CN.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [159859.CN](https://longbridge.com/en/quote/159859.CN.md)
- [588860.CN](https://longbridge.com/en/quote/588860.CN.md)
- [159615.CN](https://longbridge.com/en/quote/159615.CN.md)
- [588250.CN](https://longbridge.com/en/quote/588250.CN.md)
- [513120.CN](https://longbridge.com/en/quote/513120.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [512290.CN](https://longbridge.com/en/quote/512290.CN.md)
- [516820.CN](https://longbridge.com/en/quote/516820.CN.md)
- [02509.HK](https://longbridge.com/en/quote/02509.HK.md)

## Related News & Research

- [Analyst Reiterates Buy on Microbix, Citing Temporary China Slowdown and Growing Diversified Demand](https://longbridge.com/en/news/286665358.md)
- [Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended](https://longbridge.com/en/news/286268861.md)
- [HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations](https://longbridge.com/en/news/286197909.md)
- [Manulife Singapore to offer multi-cancer blood test starting May](https://longbridge.com/en/news/286710691.md)
- [20:03 ETHarbour BioMed Announces Promising Preclinical Data for LET003, Its First AI-Enabled Drug Candidate](https://longbridge.com/en/news/286688082.md)